Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 2606 |
| INN | Abagovomab |
| Status | Terminated |
| Drug code(s) | None |
| Brand name | None |
| mAb sequence source | mAb murine |
| General Molecular Category | Vaccine, Anti-idiotype antibody |
| Format, general category | Full length Ab |
| Format details | None |
| Isotype (Fc) | IgG1 |
| Light chain isotype | kappa |
| Linker | None |
| Ave. DAR | None |
| Conjugated/fused moiety | None |
| Discovery method/technology | None |
| Target(s) | MUC16 idiotype |
| Indications of clinical studies | Ovarian cancer |
| Primary therapeutic area | Cancer |
| Most advanced stage of development (global) | Terminated at Phase 2/3 |
| Status | Inactive |
| Start of clinical phase (IND filing or first Phase 1) | December 15, 2002 |
| Start of Phase 2 | |
| Start of Phase 3 | December 15, 2006 |
| Date BLA/NDA submitted to FDA | |
| Year of first approval (global) | None |
| Date of first US approval | |
| INN, US product name | None |
| US or EU approved indications | None |
| Company | Menarini Group |
| Licensee/Partner | Memorial Sloan Kettering Cancer Center |
| Comments about company or candidate | Menarini terminates the phase III MIMOSA trial in Ovarian cancer in USA and European Union (NCT00418574, started in Dec 2006). NCT00058435 Phase 1 started in Dec 2002; non-commercial sponsor. |
| Full address of company | Florence, Italy Europe Italy https://www.menarini.com/en-us/about-us |
Abagovomab is an anti-idiotypic monoclonal antibody that mimics a specific epitope on the tumour-associated antigen, CA125. Cancer vaccine mechanism of action
| Anticipated events | None |
| Factor(s) contributing to discontinuation | None |